Sec Form 4 Filing - Arch Venture Fund VII LP @ Syros Pharmaceuticals, Inc. - 2016-07-06

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Arch Venture Fund VII LP 2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [ SYRS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 8755 WEST HIGGINS ROAD, SUITE 1025 3. Date of Earliest Transaction (MM/DD/YY) 07/06/2016 (Street) CHICAGO, IL60631 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/06/2016 C 266,666 A 479,999 D ( 5 ) Common Stock 07/06/2016 C 1,333,333 A 1,813,332 D ( 5 ) Common Stock 07/06/2016 C 2,000,000 A 3,813,332 D ( 5 ) Common Stock 07/06/2016 C 423,805 A 4,237,137 D ( 5 ) Common Stock 07/06/2016 P 400,000 A $ 12.5 4,637,137 D ( 5 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A-1 Preferred Stock ( 1 ) 07/06/2016 C 1,000,000 ( 1 ) ( 1 ) Common Stock 266,666 $ 0 0 D ( 5 ) Series A-2 Preferred Stock ( 2 ) 07/06/2016 C 5,000,000 ( 2 ) ( 2 ) Common Stock 1,333,333 $ 0 0 D ( 5 ) Series A-3 Preferred Stock ( 3 ) 07/06/2016 C 7,500,000 ( 3 ) ( 3 ) Common Stock 2,000,000 $ 0 0 D ( 5 ) Series B Preferred Stock ( 4 ) 07/06/2016 C 1,589,269 ( 4 ) ( 4 ) Common Stock 423,805 $ 0 0 D ( 5 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Arch Venture Fund VII LP 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X ARCH Venture Partners VII, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X ARCH Venture Partners VII, LLC 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X CRANDELL KEITH 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X BYBEE CLINTON 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X Signatures ARCH Venture Fund VII, L.P. By: ARCH Venture Partners VII, L.P. By: /s/Mark McDonnell, as Attorney-in-Fact for Keith Crandell, the Mgng Dir of ARCH VII LLC, the GP of ARCH Partners VII, the GP of ARCH Fund VII Name: Mark McDonnell Title: Attorney-in fact 07/06/2016 Signature of Reporting Person Date ARCH Venture Partners VII, L.P. By: ARCH Venture Partners VII, LLC By: /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH VII LLC, the general partner of ARCH Partners VII Name: Mark McDonnell Title: Attorney-in fact 07/06/2016 Signature of Reporting Person Date ARCH Venture Partners VII, LLC By: /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH VII LLC Name: Mark McDonnell Title: Attorney-in fact 07/06/2016 Signature of Reporting Person Date /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell Keith Crandell 07/06/2016 Signature of Reporting Person Date /s/ Mark McDonnell, as Attorney-in-Fact for Clinton Bybee 07/06/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. ( 2 )The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. ( 3 )The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. ( 4 )Th e Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. ( 5 )These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.